Seneca Therapeutics is developing SVV-001, an oncolytic virus that selectively binds tumor endothelial marker 8 (TEM8), infects and kills tumor cells, and elicits a systemic anti-tumor immune response. Preclinical studies reportedly show SVV-001 can convert immunologically 'cold' tumors into 'hot' tumors and, when combined with nivolumab and ipilimumab, eradicate tumors and extend survival. The company has started a Phase I/II trial (NCT06889493) assessing SVV-001 plus nivolumab and ipilimumab in high-grade neuroendocrine neoplasms and plans a companion diagnostic to identify TEM8-expressing patients. The trial design includes three single-ascending dose cohorts, two multiple-ascending dose cohorts, and a planned 15-patient expansion, with enrollment of 21–30 patients in the dose cohorts. Seneca anticipates initial data readout in the second half of 2026 or the first half of 2027. The recently closed financing provides cash runway through 2027 to complete the ongoing trial. Seneca Therapeutics is a clinical-stage biopharmaceutical company based in Blue Bell, Pennsylvania focused on developing novel oncolytic immunotherapeutics and armed derivatives for difficult-to-treat solid tumors. Its first candidate is Seneca Valley Virus (SVV/SVV-001), an oncolytic immunotherapeutic that replicates in and eliminates tumor cells. In October 2022 the company received FDA clearance to begin a Phase I/II clinical study of SVV-001 in combination with a checkpoint inhibitor in 2023. The company is advancing plans to test armed derivatives that selectively express gene products inserted into the SVV-001 genome to create additional anti-tumor effects. Seneca has been funded through angel and bridge financing to support its clinical programs. Seneca Therapeutics is developing a pipeline of cancer agents based on the nonpathogenic Seneca Valley Virus isolate 001 (SVV-001). The company says SVV-001 selectively kills cancer cells expressing the TEM-8 receptor and stimulates immune responses, and is being paired with a companion diagnostic. SVV-001 has demonstrated safety and efficacy in dozens of relevant animal tumor models and shown safety and promising signs of efficacy in clinical trials. The first product, SVV-001 itself, was anticipated to enter later-stage clinical trials in 2021. The company notes that $30M has been invested into SVV since its discovery in 2001. Leadership includes CEO James Hussey (joined 2020) and founder/CSO Dr. Paul Hallenbeck.

Total raised

$4M

Funding rounds

3

Latest round

Series B

Latest activity

Aug 2025